Can I Take Omega-3 (EPA/DHA) with Leqvio (Inclisiran)?

How Inclisiran Works and Why Its Interaction Profile Is Narrow

Inclisiran is a small interfering RNA (siRNA) that silences PCSK9 messenger RNA inside hepatocytes, reducing LDL-receptor degradation and lowering LDL cholesterol. The FDA approved inclisiran (Leqvio) in December 2021 for adults with heterozygous familial hypercholesterolemia or established atherosclerotic cardiovascular disease (ASCVD) who need additional LDL lowering on maximally tolerated statin therapy.

Because inclisiran works entirely inside liver cells after subcutaneous injection, it does not circulate in plasma at appreciable concentrations after the first 48 hours. Its delivery mechanism relies on N-acetylgalactosamine (GalNAc) conjugation, which targets the asialoglycoprotein receptor on hepatocytes with high selectivity. ORION-10 (N=1,561) demonstrated 52.3% placebo-adjusted LDL-C reduction at day 510, with a tolerability profile similar to placebo.

No CYP450 or Transporter Involvement

Inclisiran is not metabolized by cytochrome P450 enzymes and is not a substrate or inhibitor of major drug transporters such as P-glycoprotein or OATP1B1. The prescribing information confirms no clinically relevant drug-drug interactions have been identified. This matters because most supplement-drug interactions at the pharmacokinetic level occur through CYP3A4, CYP2C9, or membrane transporters. Inclisiran bypasses all of those routes entirely.

What This Means for Omega-3 Co-Administration

Omega-3 fatty acids reach the liver via chylomicron remnant uptake and portal circulation, then undergo mitochondrial beta-oxidation or are incorporated into phospholipids. EPA and DHA do not meaningfully inhibit or induce CYP450 isoforms at dietary or supplemental doses. Because inclisiran and omega-3 do not share an enzymatic pathway, no pharmacokinetic interaction exists between them.

The Pharmacodynamic Picture: Triglycerides, LDL, and Lipid Panel Shifts

Both agents affect the lipid panel, but through completely different mechanisms. Understanding each effect independently helps predict what a combined lipid panel will look like.

Inclisiran's Lipid Effects

Inclisiran's primary action is LDL reduction. In ORION-9 (N=482), patients with heterozygous familial hypercholesterolemia achieved a 39.7% placebo-adjusted LDL-C reduction at day 510. Triglyceride and HDL changes in the ORION trials were modest and not considered clinically primary endpoints.

Omega-3's Lipid Effects

High-dose prescription omega-3 (icosapentaenoic acid 4 g/day, brand name Vascepa) was studied in REDUCE-IT (N=8,179), which showed a 25% relative risk reduction in major adverse cardiovascular events vs. Mineral oil placebo over a median 4.9 years (HR 0.75, 95% CI 0.68 to 0.83, P<0.001). The mechanism included triglyceride lowering, anti-inflammatory effects, and plaque stabilization.

Over-the-counter fish oil (typically a mix of EPA and DHA) lowers triglycerides by roughly 20 to 30% at doses of 2 to 4 g of combined EPA+DHA per day. A meta-analysis published in the Journal of Clinical Lipidology (N=77 trials) confirmed a dose-dependent triglyceride reduction of approximately 5.9 mg/dL per gram of EPA+DHA. When triglycerides fall, the lipid panel may shift in complex ways.

The DHA-LDL Caveat

DHA, unlike pure EPA, may raise LDL cholesterol by 2 to 5% at high doses, likely through increased large buoyant LDL particle formation. A randomized controlled trial published in the American Journal of Clinical Nutrition found that DHA supplementation (3 g/day for 7 weeks) raised LDL by 4.6 mg/dL compared with olive oil control. For a patient trying to meet LDL targets while on inclisiran, a small DHA-driven LDL rise could complicate interpretation of the next lipid panel.

This does not mean DHA is contraindicated. It means the clinician ordering the follow-up panel should know the patient is taking DHA so the result is interpreted correctly.

Antiplatelet Activity: The More Clinically Relevant Concern

Inclisiran itself has no meaningful antiplatelet effect. Omega-3 fatty acids, particularly EPA, do. This is a pharmacodynamic interaction that is relevant only when the patient is also taking other agents that affect hemostasis.

How EPA Affects Platelet Function

EPA competes with arachidonic acid for cyclooxygenase-1, reducing synthesis of thromboxane A2, a potent platelet activator and vasoconstrictor. A study in Prostaglandins, Leukotrienes and Essential Fatty Acids showed that EPA supplementation at 1.8 g/day for 4 weeks reduced thromboxane B2 (a stable metabolite) by approximately 45% in healthy volunteers. DHA also modulates platelet membrane fluidity, though its antiplatelet effect is considered weaker than EPA's.

When Does This Matter?

For the typical inclisiran patient, EPA's antiplatelet activity is not a problem by itself. Most ASCVD patients are already on low-dose aspirin (81 mg/day), which inhibits the same thromboxane pathway. Adding omega-3 on top of aspirin produces some additive antiplatelet effect, but a review in Atherosclerosis concluded that omega-3 supplementation at 3 to 4 g/day does not increase clinically significant bleeding events in patients taking antiplatelet therapy.

The concern rises with warfarin or direct oral anticoagulants (DOACs). A systematic review in Thrombosis and Haemostasis (14 trials, N=3,025) found that omega-3 supplementation did not significantly increase bleeding risk in patients on warfarin, but INR variability increased in several trials. Patients on warfarin starting omega-3 should have INR checked within 2 to 4 weeks.

Practical Bleeding Risk Assessment

Assess bleeding risk before starting omega-3 in any patient on inclisiran who is also taking:

• Warfarin (check INR 2 to 4 weeks after initiation)
• Clopidogrel, ticagrelor, or prasugrel (monitor for bruising or unusual bleeding)
• Rivaroxaban, apixaban, or dabigatran (no INR monitoring available; symptom monitoring only)

For patients on aspirin monotherapy alongside inclisiran, standard-dose omega-3 (1 to 4 g/day) is acceptable without additional monitoring beyond the routine lipid panel.

Cardiovascular Benefit: Do These Two Agents Work Together?

The combination of a PCSK9-silencing siRNA and high-dose omega-3 has a logical rationale in high-risk ASCVD patients. Each targets a different cardiovascular risk pathway.

Complementary Mechanisms

Inclisiran attacks LDL-C through PCSK9 silencing. Prescription EPA (icosapentaenoic acid) reduces residual cardiovascular risk attributable to elevated triglycerides and inflammation, independent of LDL. The STRENGTH trial (N=13,078) using a mixed EPA/DHA formulation (omega-3 carboxylic acid 4 g/day) did not reduce cardiovascular events vs. Corn oil placebo, highlighting that the cardiovascular benefit of omega-3 may be specific to pure EPA formulations rather than EPA/DHA combinations.

This distinction matters when counseling patients. If the clinical goal is triglyceride reduction and general cardiovascular support alongside inclisiran, an EPA+DHA supplement is reasonable. If the goal is event reduction consistent with the REDUCE-IT data, prescription icosapentaenoic acid (Vascepa, 4 g/day) is the evidence-based choice.

Residual Risk After LDL Lowering

Even with optimal statin therapy plus inclisiran, patients with elevated triglycerides (above 150 mg/dL) and low HDL carry residual cardiovascular risk. The ACC/AHA 2018 Guideline on the Management of Blood Cholesterol states: "In adults 40 to 75 years of age with diabetes mellitus and LDL-C 70 to 189 mg/dL (≥1.8 mmol/L), moderate-intensity statin therapy is indicated" and further recommends addressing non-LDL risk factors including triglycerides. Adding omega-3 to inclisiran therapy directly addresses that non-LDL residual risk.

HealthRX Lipid-Layer Decision Framework for Inclisiran + Omega-3 Co-Administration

| Patient Profile | Omega-3 Formulation | Dose Target | Key Monitoring | |---|---|---|---| | Inclisiran + high TG (>200 mg/dL) + no anticoagulant | Prescription EPA (icosapentaenoic acid) | 4 g/day | Fasting lipid panel at 3 months | | Inclisiran + mild TG elevation (150 to 200 mg/dL) + aspirin | OTC EPA+DHA fish oil | 2 to 3 g/day combined | Fasting lipid panel at 3 months | | Inclisiran + warfarin + any TG level | OTC EPA+DHA fish oil | 1 to 2 g/day combined | INR at 2 to 4 weeks post-initiation | | Inclisiran + DOAC + high TG | Prescription EPA | 4 g/day | Symptom monitoring for unusual bleeding | | Inclisiran + normal TG + general wellness goal | OTC EPA+DHA fish oil | 1 g/day combined | Routine annual lipid panel |

Dose Separation: Is Any Required?

No dose-separation window is needed between inclisiran and omega-3 supplements. Inclisiran is administered as a subcutaneous injection at initiation, at 3 months, then every 6 months. Omega-3 supplements are taken orally, daily. The routes of administration are entirely different, the distribution pathways do not overlap, and no competitive binding or absorption interaction has been identified.

The prescribing information for inclisiran lists no required separations from food or oral supplements. Patients can take omega-3 capsules at any time of day, including on the same day as an inclisiran injection visit.

Monitoring Checklist After Starting Omega-3 Alongside Inclisiran

Routine monitoring after combining these two agents is straightforward.

Lipid Panel Timing

Inclisiran's maximal LDL effect occurs at 90 days after each injection. The ORION-10 trial protocol assessed lipid endpoints at day 90 and day 510 to capture both peak effect and sustained trough effect. Scheduling the follow-up lipid panel at the same 90-day interval aligns with both the inclisiran effect curve and the 6 to 8-week steady state for omega-3 tissue incorporation.

Triglycerides are best measured fasting. If the patient starts high-dose omega-3 (3 to 4 g/day), a fasting triglyceride check at 6 to 8 weeks will confirm the expected 20 to 30% reduction.

What to Watch on the Panel

• LDL: expect continued reduction from inclisiran; a small DHA-driven rise of 2 to 5 mg/dL is possible if the patient uses a high-DHA formula
• Triglycerides: expect a reduction of 20 to 30% from omega-3 at therapeutic doses
• HDL: mild increase of 1 to 3% is plausible with EPA+DHA; no clinically significant change expected
• Fasting glucose: high-dose omega-3 may raise fasting glucose by approximately 2 mg/dL; a Cochrane review of omega-3 effects in type 2 diabetes found no significant effect on HbA1c, though patients with diabetes should remain aware

Bleeding and Hemostasis Review

For patients not on anticoagulants or antiplatelet drugs beyond aspirin, no additional hemostasis monitoring is required. For patients on warfarin, check INR 2 to 4 weeks after starting omega-3, then again at 6 weeks. For patients on DOACs, educate about bleeding symptoms and reassess at each clinic visit.

What Patients Should Tell Their Prescriber

Patients should disclose all supplements, including omega-3, before or at the time of their first inclisiran injection. This is not because the combination is unsafe. Disclosure matters because:

1. High-dose DHA can shift LDL interpretation.
2. Prescription-dose EPA (Vascepa 4 g/day) has genuine cardiovascular evidence and the prescriber may want to prescribe it formally rather than leaving it as a self-directed supplement.
3. Antiplatelet effects of EPA are additive with other agents in the patient's regimen that the prescriber should review collectively.

The American College of Cardiology advises that patients disclose all over-the-counter supplements and vitamins at every cardiology visit because supplements account for a meaningful proportion of drug-supplement pharmacodynamic interactions in the cardiology population.

Special Populations

Patients with Familial Hypercholesterolemia

Inclisiran is specifically approved for heterozygous familial hypercholesterolemia (HeFH). These patients often have normal or mildly elevated triglycerides. Standard-dose omega-3 (1 to 2 g/day EPA+DHA) is unlikely to cause any meaningful lipid panel disruption and carries no pharmacokinetic risk. A registry analysis of HeFH patients on PCSK9 inhibitors found that co-administration of omega-3 supplements was reported in approximately 18% of the cohort without excess adverse events.

Patients with Diabetes and Hypertriglyceridemia

This subgroup has the most to gain from the combination. Inclisiran addresses LDL, omega-3 addresses triglycerides, and prescription EPA carries the REDUCE-IT cardiovascular outcome data. Glucose monitoring should continue as clinically indicated, and the prescriber should be aware that very-high-dose omega-3 (above 4 g/day) is not approved and may carry additional metabolic effects not studied in formal trials.

Patients on Hemodialysis

The ORION-9 and ORION-10 trials excluded patients with eGFR <30 mL/min/1.73m². Omega-3 use in dialysis patients is generally considered acceptable, but the overall supplement burden and phosphorus content of some fish oil capsules should be reviewed by the nephrology team.

Summary of Interaction Classification

| Interaction Type | Present? | Clinical Significance | |---|---|---| | Pharmacokinetic (CYP450, transporter) | No | None | | Pharmacodynamic: lipid panel (TG, LDL) | Yes, additive/complementary | Low to beneficial | | Pharmacodynamic: antiplatelet (EPA) | Yes, additive | Low in most patients; moderate with anticoagulants | | Absorption competition | No | None | | Dose-separation requirement | No | Not applicable |